South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014

South African Medical Journal

Volumn 104, Issue 8, 2014, Pages 537-543

  Guidozzi, F ^a   Alperstein, A ^b   Bagratee, J S ^c   Dalmeyer, P ^d   Davey, M ^b   de Villiers, T J ^b   Hirschowitz, S ^b   Kopenhager, T ^b   Moodley, S P ^b   Roos, P ^b   Shaw, A ^b   Shimange, O ^b   Smith, T ^a   Thomas, C ^b   Titus, J ^c   van der Spuy, Z ^d   van Waart, J ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b Department of Obstetrics and Gynaecology Nelson Mandela School of Medicine College of Health Sciences University of KwaZulu Natal ^*  (South Africa)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Menopause therapy

Indexed keywords

BAZEDOXIFENE; CALCIUM; GABAPENTIN; OSPEMIFENE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VITAMIN D; HORMONE;

ALZHEIMER DISEASE; ANDROGEN THERAPY; ARTICLE; BREAST CANCER; CANCER SURVIVOR; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; DETRUSOR DYSSYNERGIA; DIABETES MELLITUS; ENDOMETRIUM CANCER; ESTROGEN THERAPY; HORMONAL THERAPY; HOT FLUSH; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LUNG CANCER; MENOPAUSAL SYNDROME; OVARY CARCINOMA; PREMATURE OVARIAN FAILURE; SLEEP DISORDER; VAGINA ATROPHY; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; FEMALE; MEDICAL SOCIETY; MENOPAUSE; POSTMENOPAUSE; PRACTICE GUIDELINE; SOUTH AFRICA;

FEMALE; HORMONES; HUMANS; MENOPAUSE; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL; SOUTH AFRICA;

EID: 84905258301     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: 10.7196/samj.8423     Document Type: Article

References (66)

1. Utian W, Woods NF. Impact of hormone therapy on quality of life after menopause. Menopause 2013;20(10):109-110. [http://dx.doi.org/10.1097/GME.0b013e318298debe]
2. Davis SR, Castelo-Branco R, Chearaur P, et al. Understanding weight gain at menopause. Climacteric 2012;15(5):419-429. [http://dx.doi.org/10.3109/13697137.2012.707385]
3. De Villiers TJ, Gass MLS, Haine CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16(2):203-204. [http://dx.doi.org/10.3109/13697137.2013.771520]
4. Board of Trustees of North American Menopause Society. Treatment of menopause-associated vasomotor symptoms: Position statement of the North American Menopause Society. Menopause 2004;11(1):11-33. [http://dx.doi.org/10.1097/01.GME.0000108177.85442.71]
5. North American Menopause Society. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 2012;19(3):257-271. [http://dx.doi.org/10.1097/ gme.0b013e31824b970]
6. De Villiers T, Pines A, Panay N, et al. Updated IMS recommendations on post-menopausal hormone therapy and preventative strategies for midlife health. Climacteric 2013;16(3):316-337. [http://dx.doi. org/10.3109/13697137.2013.795683]
7. ACOG Practice Bulletin No. 141. Management of menopausal symptoms. Obstet Gynecol 2014;123(1):202-216. [http://dx.doi.org/10.1097/01.AOG.0000441353.20693.78]
8. Guidozzi F. Sleep and sleep disorders in menopausal women. Climateric 2013;16(2):214-219. [http:// dx.doi.org/10.3109/13697137.2012.753873]
9. Sturdee DW, Panay N. Recommendation for the management of postmenopausal vaginal atrophy. Climateric 2010;13(6):509-522. [http://dx.doi.org/10.3109/13697137.2010.522875]
10. Nelson HD. Walker M, Zakher B, Mitchell J. Menopausal hormone therapy for the primary prevention of chronic conditions: Systematic review to update the US Preventative Services Task Force recommendations. Ann Intern Med 2012;157(2):104-113. [http://dx.doi.org/10.7326/0003-4819-157-2-201207170-00466]
11. Hodis HN. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynaecol 2008;51(3):564-580. [http://dx.doi.org/10.1097/GRF.0b013e318181de86]
12. Grodstein, F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: The role of time since menopause and age at hormone initiation. J Womens Health 2006;15(1):35-44. [http://dx.doi. org/10.1001/archinte.168.8.861]
13. Hodis HN, Mack NJ. A 'window of opportunity': The reduction of coronary heart disease and total mortality with menopausal therapies is age-and time-dependent. Brain Res 2001;1379:244-252. [http://dx.doi.org/10.1016/j.brainres.2010.10.076]
14. Schierbeck LL, Rejnmark L, Toffeng CL. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: A randomized trial. BMJ 2012;345:e6409. [http://dx.doi. org/10.1136/bmj.e6409]
15. Hodis HN, Collins P, Mack WJ, Schierbeck LL. The window of opportunity for coronary heart disease prevention with hormone therapy: Past, present and future in perspective. Climateric 2012;15(3):217-228. [http://dx.doi.org/10.3109/13697137.2012.656401]
16. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and year since menopause. JAMA 2007;297(13):1465-1477. [http://dx.doi.org/10.1001/ jama.297.13.1465]
17. Margolis KL. Effect of oestrogen plus progestin on the incidence of diabetes in post-menopausal women: Results from the Women's Health Initiative hormone trial. Diabetologica 2004;47(7):1175-1187. [http://dx.doi.org/10.1007/s00125-004-1448-x]
18. Simon JA, Hsia J, Canley JA, et al. Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103(5):638-642. [http://dx.doi. org/10.1161/01.CIR.103.5.638]
19. Lobo RA. The risk of stroke in post-menopausal women receiving hormonal therapy. Climateric 2009;12(Suppl 1):81-95. [http://dx.doi.org/10.1080/13697130902835376]
20. Lisabeth L, Bushnell C. Stroke risk in women: The role of menopause and hormone therapy. Lancet Neurol 2012;11(1):82-91. [http://dx.doi.org/10.1016/S1474-4422(11)70269-1]
21. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: Role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168(8):861-866. [http://dx.doi.org/10.1001/archinte.168.8.861]
22. Viscoli CM, Brass LM, Kernan WN, et al. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001;345(17):1243-1249. [http://dx.doi.org/10.1056/NEJMoa010534]
23. Lakkegaard E, Jovanovic Z, Heitmann BL, et al. Increased risk of stroke in hypertensive women using hormone therapy. Arch Neurol 2003;60(10):1370-1384. [http://dx.doi.org/10.1001/ archneur.60.10.1379]
24. Scarabin PY, Oger E, Plu-Burean G, on behalf of the Estrogen and romboembolism Risk (ESTHER) study group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362(9382):428-432. [http://dx.doi.org/10.1016/S0140-6736(03)14066-4]
25. Canonico M, Plu-Bureau G, Lowe GD, Scarabin P. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: Systematic review and meta-analysis. BMJ 2008;336(7655):227-1231. [http://dx.doi.org/10.1136/bmj.39555.441944.BE]
26. Cushman M, Kuller LH, Prentice R, et al., for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292(13):1573-1580. [http://dx.doi. org/10.1001/jama.292.13.1573]
27. Canonico M, Plu-Bureau G, Scarabin PY. Progestogens and venous thromboembolism among women using hormone therapy. Maturitas 2011;70(4):354-360. [http://dx.doi.org/10.1016/j. maturitas.2011.10.002]
28. Fournier A, Berrina F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008;107(1):103-111. [http://dx.doi.org/10.1007/s10549-007-9523-x]
29. Fournier A, Febre A, Mesrine S, et al. Use of different post menopausal hormone therapies and risk of histology-and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26(8):1260-1268. [http://dx.doi.org/10.1200/JCO.2007.13.4338]
30. Bush T, Whiteman M, Flaws J. Hormone replacement therapy and breast cancer: A qualitative review. Obstet Gynecol 2001;98(3):498-508. [http://dx.doi.org/10.1016/S0029-7844(01)01453-3]
31. Chlebowski RT, Hendrix SG, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women: The Women's Health Initiative randomized trial. JAMA 2003;289(24):3243-3253. [http://dx.doi.org/10.1001/jama.289.24.3243]
32. Prentice R, Chlebowski RT, Stefanick ML, et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008;167(12):1407-1411. [http://dx.doi.org/10.1093/aje/kwn090]
33. Kerlikowske K, Cook AJ, Buist DSM, et al. Breast cancer risk, breast density, menopause and postmenopausal hormone therapy use. J Clin Oncol 2010;28(24):3830-3837. [http://dx.doi. org/10.1200/JCO.2009.26.4770]
34. Buist DSM, Anderson ML, Read SL. Short term hormone therapy suspension and mammography recall: The radiological evaluation and breast density (READ) randomized trial. Ann Intern Med 2009;150(11):752-765. [http://dx.doi.org/10.7326/0003-4819-150-11-200906020-00003]
35. Henderson KD, Duan L, Sullivan-Halley J, et al. Menopausal hormone therapy use and risk of invasive colon cancer. Am J Epidemiol 2010;171(4):415-425. [http://dx.doi.org/10.1093/aje/kwp434]
36. Long MD, Martin CF, Galanko JA, Sandler RS. Hormone replacement therapy, oral contraceptive use and distal large bowel cancer: A population-based case-control study. Am J Gastroenterol 2010;105(8):1843-1850. [http://dx.doi.org/10.1038/ajg.2010.123]
37. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365(9470):1543-1551. [http://dx.doi.org/10.1016/S0140-6736(05)66455-0]
38. Hill D, Weiss NS, Beresford SAA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000;183(6):1456-1461. [http://dx.doi.org/10.1067/ mob.2000.108081]
39. Lacey JV, Mink PJ, Lubin JH, et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002;288(3):334-341. [http://dx.doi.org/10.1001/jama.288.3.334]
40. Riman T, Dickman PW, Nilsson S, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002;94(7):496-504. [http://dx.doi. org/10.1093/jnci/94.7.497]
41. Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): A post-hoc analysis of a randomized controlled trial. Lancet 2009;374(9697):1243-1251. [http://dx.doi.org/10.1016/S0140-6736(09)61526-9]
42. Van Schoultz E, Rutquist L. Menopausal hormone therapy after breast cancer: The Stockholm Randomized Trial. J Natl Cancer Inst 2005;97(7):533-535. [http://dx.doi.org/10.1093/jnci/dji071]
43. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?): A randomized comparison: Trial stopped. Lancet 2004;363(9407):453-455. [http://dx.doi.org/10.1016/ S0140-6736(04)15493-7]
44. Kenemans P, Bundred NJ, Foidart J-M, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: A double-blind randomized non-inferiority trial. Lancet Oncol 2009;10(2):135-146. [http://dx.doi.org/10.1016/S1470-2045(08)70341-3]
45. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climateric 2003;6(1):45-52. [http://dx.doi.org/10.1080/cmt.6.1.45.52]
46. Guidozzi F. Estrogen therapy in gynaecologic cancer survivors. Climateric 2013;16(6):611-617. [http:// dx.doi.org/10.3109/13697137.2013.806471]
47. Whitmer RA. Timing of hormone therapy and dementia: The critical window theory revisited. Ann Neurol 2011;69(1):163-169. [http://dx.doi.org/10.1002/ana.22239]
48. Maki PM. Hormone therapy and cognitive function: Is there a critical period for benefit? Neuroscience 2006;138(3):1027-1030. [http://dx.doi.org/10.1016/j.neuroscience.2006.01.001]
49. Ossewaarde ME, Bots ML, Verbeek M, Peeters PH. Age at menopause, cause-specific mortality and total life expectancy. Epidemiology 2005;16(4):556-562. [http://dx.doi.org/10.1097/01. ede.0000165392.35273.d4]
50. Archer D. Premature menopause increases cardiovascular risk. Climacteric 2009;12(Suppl 1):26-31. [http://dx.doi.org/10.1080/13697130903013452]
51. Gallagher JC. Effects of early menopause on bone mineral density and fractures. Menopause 2007;14(3):567-571. [http://dx.doi.org/10.1097/gme.0b013e31804c793d]
52. Grazziottin A. Menopause and sexuality: Key issues in premature menopause and beyond. Ann N Y Acad Sci 2010;1205(1):254-261. [http://dx.doi.org/10.1111/j.1749-6632.2010.05680.x]
53. Schwenkhagen A. Hormonal changes in menopause and implications on sexual health. J Sex Med 2007;4(Suppl 3):220-226. [http://dx.doi.org/10.1111/j.1743-6109.2007.00448.x]
54. Davis SR. Should women receive androgen replacement therapy, and if so, how? Clin Endocrinol 2010;72(2):149-154. [http://dx.doi.org/10.1111/j.1365-2265.2009.03670.x]
55. Panay N, Al-Azzani F, Bouchard C, et al. Testosterone treatment of HSDD in naturally menopausal women: The ADORE study. Climateric 2010;13(2):121-131. [http://dx.doi.org/10.3109/13697131003675922]
56. Davis SR. The effects of tibolone on mood and libido. Menopause 2002;9(3):162-170. [http://dx.doi. org/10.1097/00042192-200205000-00004]
57. Shu YY, Maibach H. Estrogen and skin. Am J Clin Dermatology 2011;12(5):297-311. [http://dx.doi. org/10.2165/11589180-000000000-00000]
58. Meurman JH, Tarkkila L, Tritinen A. The menopause and oral health. Maturitas 2009;63(1):56-62. [http://dx.doi.org/10.1016/j.maturitas.2009.02.009]
59. Boothby LA. Bioidentical hormone therapy: A panacea that lacks supportive evidence. Curr Opin Obstet Gynecol 2008;20(4):400-407. [http://dx.doi.org/10.1097/GCO.0b013e3283081ae9]
60. ACOG Committee of Gynecologic Practice. Committee opinion No. 322: Compounded bioidentical hormones. Obstet Gynecol 2005;106(5):1139-1140.
61. Taylor M. Unconventional estrogens: Estriol, biest and triest. Clin Obstet Gynecol 2001;44(4):864-879. [http://dx.doi.org/10.1097/00003081-200112000-00024]
62. Sturdee DW, Pines A, on behalf of the International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal hormone therapy and preventative strategies for midlife health. Climateric 2011;14(3):302-320. [http://dx.doi.org/10.3109/13697137.2011.570590]
63. The North American Menopause Society 2012 Hormone Therapy Position Statement Advisor Panel. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 2012;19(3):257-271. [http://dx.doi.org/10.1097/gme.0b013e31824b970a]
64. Nedrow A. Complementary and alternative therapies for the management of menopause-related symptoms: A systemic evidence review. Arch Intern Med 2006;166(14):1453-1465. [http://dx.doi.org/10.1001/archinte.166.14.1453]
65. Nelson HD. Non-hormonal therapies for menopausal hot Thashes: A systematic review and metaanalysis. JAMA 2006;295(17):2057-2071. [http://dx.doi.org/10.1001/jama.295.17.2057]
66. Messina M, McCaskill-Stevens W, Lampe JW. Addressing the soy and breast cancer relationship: Review, commentary, and workshop proceedings. J Natl Cancer Inst 2006;98(18):1275-1284. [http:// dx.doi.org/10.1093/jnci/djj356]